{"analyses":[{"ciLowerLimit":"0.71","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.03","estimateComment":"Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by geographic region (Asia vs. Non-Asia), tumor staging (II vs. III vs. IVa), and chemotherapy backbone (XP/FP vs. FLOT)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.04493","pValueComment":"One-sided p-value based on log-rank test stratified by geographic region (Asia vs. Non-Asia), tumor staging (II vs. III vs. IVa), and chemotherapy backbone (XP/FP vs. FLOT)","paramType":"Hazard Ratio (HR)","paramValue":"0.86","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"NA = Median and upper limit were not reached at the data cut-off due to insufficient number of participants with an event","groupId":"OG000","lowerLimit":"59.2","upperLimit":"NA","value":"NA"},{"comment":"NA = Upper limit was not reached at the data cut-off due to insufficient number of participants with an event","groupId":"OG001","lowerLimit":"42.8","upperLimit":"NA","value":"55.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"502"},{"groupId":"OG001","value":"505"}],"units":"Participants"}],"description":"OS was defined as the time from randomization to death due to any cause. OS was presented for the Pembrolizumab+XP/FP and Placebo+XP/FP treatment arms in combination with the Pembrolizumab+FLOT and Placebo+FLOT Cohorts.","dispersionType":"95% Confidence Interval","groups":[{"description":"Neoadjuvant and adjuvant pembrolizumab+XP/FP and neoadjuvant and adjuvant pembrolizumab+FLOT Cohort treatment arms combined","id":"OG000","title":"Pembrolizumab + XP/FP and Pembrolizumab + FLOT Cohort Combined"},{"description":"Neoadjuvant and adjuvant placebo+XP/FP and neoadjuvant and adjuvant placebo+FLOT Cohort treatment arms combined","id":"OG001","title":"Placebo + XP/FP and Placebo + FLOT Cohort Combined"}],"paramType":"MEDIAN","populationDescription":"The analysis population consisted of all randomized participants in the Pembrolizumab+XP/FP and Placebo+XP/FP treatment arms in combination with the Pembrolizumab+FLOT and Placebo+FLOT Cohorts, as pre-specified in the protocol.","reportingStatus":"POSTED","timeFrame":"Up to approximately 75 months","title":"Overall Survival (OS) - Pembrolizumab+XP/FP and Placebo+XP/FP Treatment Arms in Combination With the Pembrolizumab+FLOT and Placebo+FLOT Cohorts","type":"SECONDARY","unitOfMeasure":"Months"}